Controlled clinical trial of cannabidiol in Huntington's disease

Consroe, Paul; Laguna, Joan; Allender, James; Snider, Stuart R.; Stern, Lawrence Z.; Sandyk, Reuven; Kennedy, Kurt; Schram, Karl H.

doi:10.1016/0091-3057(91)90386-g

Cited by 287 publications

(205 citation statements)

References 19 publications

Supporting

Mentioning

181

Contrasting

Unclassified

Order By: Relevance

“…Moreover, clinical trials with CBD have been conducted in humans with epilepsy (39) and Huntington's disease (40), and it was found that chronic oral administration of CBD, up to 10 mg͞kg per day for 6 weeks, had no side effects. Interestingly, one paper describes that feeding 300 or 600 mg CBD to healthy human volunteers resulted in elevated plasma cortisol levels (41), yet another factor that may contribute to its anti-inflammatory͞immunosuppressive actions.…”

Section: Discussionmentioning

confidence: 99%

The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis

Malfait¹,

Gallily²,

Sumariwalla³

et al. 2000

Proc. Natl. Acad. Sci. U.S.A.

589

428

View full text Add to dashboard Cite

The therapeutic potential of cannabidiol (CBD), the major nonpsychoactive component of cannabis, was explored in murine collagen-induced arthritis (CIA). CIA was elicited by immunizing DBA͞1 mice with type II collagen (CII) in complete Freund's adjuvant. The CII used was either bovine or murine, resulting in classical acute CIA or in chronic relapsing CIA, respectively. CBD was administered after onset of clinical symptoms, and in both models of arthritis the treatment effectively blocked progression of arthritis. CBD was equally effective when administered i.p. or orally. The dose dependency showed a bell-shaped curve, with an optimal effect at 5 mg͞kg per day i.p. or 25 mg͞kg per day orally. Clinical improvement was associated with protection of the joints against severe damage. Ex vivo, draining lymph node cells from CBD-treated mice showed a diminished CII-specific proliferation and IFN-␥ production, as well as a decreased release of tumor necrosis factor by knee synovial cells. In vitro effects of CBD included a dose-dependent suppression of lymphocyte proliferation, both mitogen-stimulated and antigen-specific, and the blockade of the Zymosan-triggered reactive oxygen burst by peritoneal granulocytes. It also was found that CBD administration was capable of blocking the lipopolysaccharide-induced rise in serum tumor necrosis factor in C57͞BL mice. Taken together, these data show that CBD, through its combined immunosuppressive and anti-inflammatory actions, has a potent anti-arthritic effect in CIA.

show abstract

Section: Discussionmentioning

confidence: 99%

The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis

Malfait¹,

Gallily²,

Sumariwalla³

et al. 2000

Proc. Natl. Acad. Sci. U.S.A.

589

428

View full text Add to dashboard Cite

show abstract

“…In this study, CBD at an average daily dose of about 700 mg/day was neither symptomatically effective nor toxic in neuroleptic-free patients with HD. 49 Afterwards, this field of research was apparently abandoned until recently, when CBD's neuroprotective effects began to be reported in animal models of Parkinson's disease.…”

Section: Action On Movement Disordersmentioning

confidence: 99%

“…The reports in this field were maintained mainly by Brazilian researchers investigating the anxiolytic and antipsychotic properties of CBD and by a few studies about its effects in motor diseases conducted by Consroe et al 48,49 1. Anxiolytic action In 1974, an interactive study between CBD and THC, per os, in healthy volunteers, gave the first clue that CBD could act as an anxiolytic drug.…”

Section: Sedative Actionmentioning

confidence: 99%

Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action

Zuardi

2008

Rev. Bras. Psiquiatr.

356

302

View full text Add to dashboard Cite

“…Participants completed only one session per week to avoid potential carryover effects resulting from CBD's long terminal half-life (21-33 h; Aguerell et al, 1986;Consroe et al, 1991). Prior to the first laboratory session, participants completed one or two practice sessions during which they were familiarized with the study tasks and procedures (no cannabis or capsules were administered).…”

Section: Study Design and Proceduresmentioning

confidence: 99%

Oral Cannabidiol does not Alter the Subjective, Reinforcing or Cardiovascular Effects of Smoked Cannabis

Haney

Malcolm

Babalonis

et al. 2015

Neuropsychopharmacol

186

183

View full text Add to dashboard Cite

Cannabidiol (CBD), a constituent of cannabis with few psychoactive effects, has been reported in some studies to attenuate certain aspects of Δ 9 -tetrahydrocannabinol (THC) intoxication. However, most studies have tested only one dose of CBD in combination with one dose of oral THC, making it difficult to assess the nature of this interaction. Further, the effect of oral CBD on smoked cannabis administration is unknown. The objective of this multi-site, randomized, double-blind, within-subject laboratory study was to assess the influence of CBD (0, 200, 400, 800 mg, p.o.) pretreatment on the reinforcing, subjective, cognitive, and physiological effects of smoked cannabis (0.01 (inactive), 5.30-5.80% THC). Non-treatment-seeking, healthy cannabis smokers (n = 31; 17M, 14 F) completed eight outpatient sessions. CBD was administered 90 min prior to cannabis administration. The behavioral and cardiovascular effects of cannabis were measured at baseline and repeatedly throughout the session. A subset of participants (n = 8) completed an additional session to measure plasma CBD concentrations after administration of the highest CBD dose (800 mg). Under placebo CBD conditions, active cannabis (1) was self-administered by significantly more participants than placebo cannabis and (2) produced significant, time-dependent increases in ratings of 'High', 'Good Effect', ratings of the cannabis cigarette (eg, strength, liking), and heart rate relative to inactive cannabis. CBD, which alone produced no significant psychoactive or cardiovascular effects, did not significantly alter any of these outcomes. Cannabis self-administration, subjective effects, and cannabis ratings did not vary as a function of CBD dose relative to placebo capsules. These findings suggest that oral CBD does not reduce the reinforcing, physiological, or positive subjective effects of smoked cannabis.

show abstract

Controlled clinical trial of cannabidiol in Huntington's disease

Cited by 287 publications

References 19 publications

The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis

The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis

Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action

Oral Cannabidiol does not Alter the Subjective, Reinforcing or Cardiovascular Effects of Smoked Cannabis

Contact Info

Product

Resources

About